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Abstract
Introduction: Streptococcus pneumoniae remains a major global health problem and a leading cause of death in
children worldwide. The factors that influence development of pneumococcal sepsis remain poorly understood,
although increasing evidence points towards a role for genetic variation in the host’s immune response. Recent
insights from the study of animal models, rare human primary immunodeficiency states, and population-based
genetic epidemiology have focused attention on the role of the proinflammatory transcription factor NF-B in
pneumococcal disease pathogenesis. The possible role of genetic variation in the atypical NF-B inhibitor IB-R,
encoded by NFKBIL2, in susceptibility to invasive pneumococcal disease has not, to our knowledge, previously been
reported upon.
Methods: An association study was performed examining the frequencies of nine common NFKBIL2
polymorphisms in two invasive pneumococcal disease case-control groups: European individuals from hospitals in
Oxfordshire, UK (275 patients and 733 controls), and African individuals from Kilifi District Hospital, Kenya (687
patients with bacteraemia, of which 173 patients had pneumococcal disease, together with 550 controls).
Results: Five polymorphisms significantly associated with invasive pneumococcal disease susceptibility in the
European study, of which two polymorphisms also associated with disease in African individuals. Heterozygosity at
these loci was associated with protection from invasive pneumococcal disease (rs760477, Mantel-Haenszel 2 × 2
c2 = 11.797, P = 0.0006, odds ratio = 0.67, 95% confidence interval = 0.53 to 0.84; rs4925858, Mantel-Haenszel 2 ×
2 c2 = 9.104, P = 0.003, odds ratio = 0.70, 95% confidence interval = 0.55 to 0.88). Linkage disequilibrium was more
extensive in European individuals than in Kenyans.
Conclusions: Common NFKBIL2 polymorphisms are associated with susceptibility to invasive pneumococcal disease
in European and African populations. These findings further highlight the importance of control of NF-B in host
defence against pneumococcal disease.
Introduction
Respiratory infection is the single largest contributor to
the global burden of disease and the leading cause of
death in children worldwide [1,2]. Streptococcus pneu-
moniae (the pneumococcus) remains the most common
cause of community-acquired pneumonia in Europe and
the United States [3]. In addition to pneumonia, pneu-
mococcal infection may also manifest as invasive dis-
ease, defined by the isolation of S. pneumoniae from a
normally sterile site such as blood (bacteraemia) or cere-
brospinal fluid (meningitis). Although asymptomatic
colonisation of the nasopharynx by the pneumococcus is
widespread in the population, invasive pneumococcal
disease (IPD) occurs in only a minority of individuals
[4,5]. The factors that influence development of invasive
disease remain poorly understood, although increasing
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evidence points towards a role for genetic variation in
the host’s immune response [5]. In particular, recent
insights from the study of animal models, rare human
primary immunodeficiency states, and population-based
genetic epidemiology have focused attention on the con-
trol of the proinflammatory transcription factor NF-B
in the development of IPD [5-10].
NF-B plays a key regulatory role in a diverse array of
cellular processes, including innate and adaptive
immune responses [11,12]. In unstimulated cells, NF-B
transcription factor subunits are prevented from binding
DNA through associations with the inhibitor of NF-B
(IB) protein family. Stimulation of a variety of immune
receptors (including Toll-like receptors, T-cell and B-
cell antigen receptors and members of the IL-1 and
TNF receptor superfamilies) leads to phosphorylation
and degradation of the IB inhibitors and release of NF-
B, which induces transcription of proinflammatory tar-
get genes [11,12]. Genes that are activated by NF-B
include those encoding cytokines (for example, IL-1, IL-
2, IL-6, TNFa) and chemokines (for example, IL-8,
RANTES), as well as acute phase response proteins,
adhesion molecules, antimicrobial peptides and induci-
ble enzymes [11,12].
Members of the IB family are characterised by multi-
ple ankyrin repeats and can be subdivided into the so-
called classical IBs (IB-a, IB-b, IB-ε), unusual IBs
(IB-R, IB-ζ, IB-L, Bcl-3), and NF-B precursors
[12,13]. Of these, the least well studied is IB-R (IB-
related), encoded by the gene NFKBIL2. The gene was
first cloned in 1995 from human lung alveolar epithelial
cells, and a modified sequence was published in 2000
[14,15]. The gene contains only three ankyrin-repeat
motifs, fewer than other IB members, and its exons
have a more complicated structure than that seen in
other IBs; overall there is only weak homology between
IB-R and other IB proteins, leading to the suggestion
that IB-R may in fact not be a member of the IB
family [15]. There is evidence, however, to support an
interaction of IB-R with NF-B. IB-R was first shown
to inhibit DNA binding by NF-B in electrophoretic
mobility shift assays [14], and overexpression of
NFKBIL2 in lung alveolar epithelial cells was subse-
quently reported to significantly upregulate the produc-
tion of RANTES (now renamed chemokine C-C motif
ligand 5 (CCL5)) protein following stimulation with
TNFa or IL-1a, although it had no effect on other NF-
B-responsive chemokines such as IL-8 [16].
Increasing evidence supports a central role for the
control of NF-B in susceptibility to severe infectious
disease in humans. A mutation in the gene NFKBIA
encoding the classical inhibitor IB-a has been
described in two patients with primary immunodefi-
ciency [8]. In addition, population-based case-control
studies of IPD have reported associations with poly-
morphisms in the IB-encoding genes NFKBIA and
NFKBIZ [9,10]. These findings raise the possibility that
variation in additional IBs such as IB-R may also con-
tribute to IPD susceptibility. No functional or disease-
associated polymorphisms have previously been reported
in NFKBIL2, however. To investigate this further we stu-
died the frequencies of NFKBIL2 polymorphisms in
individuals with IPD and healthy controls of both Eur-
opean and African descent.
Materials and methods
Sample information
The UK Caucasian IPD sample collection has been pre-
viously described [17]. Blood samples were collected on
diagnosis from all hospitalised patients with microbiolo-
gically-proven IPD (defined by the isolation of S. pneu-
moniae from a normally sterile site, most commonly
blood) as part of an enhanced active surveillance pro-
gramme between June 1995 and May 2001 in three hos-
pitals in Oxfordshire, UK: John Radcliffe Hospital,
Horton General Hospital, and Wycombe General Hospi-
tal. There were no exclusion criteria for the study. DNA
samples were available for study from 275 patients. Clin-
ical details, including age, gender, clinical presentation
and the presence of underlying risk factors, were
recorded. During the study, Oxfordshire was a region of
very low HIV prevalence and HIV testing was not routi-
nely performed. Frequencies of initial clinical presenta-
tion were as follows: pneumonia 69%, isolated
bacteraemia 15%, meningitis 11%, and other presenta-
tions 5%. The mean age of the patients was 58 years,
ranging from 0 to 94 years; 50% were male. Pneumococ-
cal serotypes were identified using polyclonal rabbit
antisera (Statens Seruminstitut, Copenhagen, Denmark).
The distribution of serotypes was very similar to that of
previous UK studies, with serotype 14 being the
commonest.
The control group comprised a combination of 163
UK healthy adult blood donors and 570 cord blood sam-
ples. For the cord samples, blood was collected anon-
ymously from the discarded umbilical cords of healthy
neonates born at the John Radcliffe Hospital, Oxford,
UK, as previously described [17]. Examination of micro-
satellite markers excluded contamination with maternal
DNA. The use of DNA from cord blood samples is
intended to reveal background population allele frequen-
cies; recent large-scale genotyping of a UK birth cohort
control group for association studies of multiple disease
phenotypes has confirmed the validity of such an
approach [18]. The mean age of the adult blood donors
was 38 years, and 50% were male; 54% of the cord
blood donors were male. Individuals of non-European
ancestry were excluded from cases and controls. The
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study was approved by the Oxford Local Research Ethics
Committee and informed consent was obtained from all
participants.
The Kenyan bacteraemia case-control collection has
also been previously described [19]. Kenyan children
(<13 years old) with bacteraemia were recruited from
Kilifi District hospital between 1998 and 2002. The 687
bacteraemic cases comprised patients with isolated
Gram-positive and Gram-negative infections, diagnosed
using standard blood culture techniques. The most fre-
quent organisms isolated were S. pneumoniae (25%),
non-Typhi Salmonella species (16%), Haemophilus influ-
enzae (14%), and Escherichia coli (8%), as well as other
less common bacteria. The 550 community controls
were individually matched to a subset of the cases on
the basis of time (recruited within 14 days), location of
homestead, age, and sex. Only children with complete
data for HIV, malnutrition, and malaria status were
included in the analysis. Ethical approval for the study
was given by the Kenya Medical Research Institute
National Scientific Steering and Research Committees
and informed consent was obtained from all
participants.
Genotyping techniques
DNA extraction from blood was performed using
Nucleon II kits (Scotlab Bioscience, Buckingham, UK).
Polymorphisms within NFKBIL2 were selected from the
dbSNP and ensembl databases on the basis of their
probable functionality [20,21], as well as to provide an
overview of linkage disequilibrium (LD) across the gene
and flanking regions. Genotyping was performed using
the Sequenom Mass-Array® MALDI-TOF primer exten-
sion assay [22]; primer sequences are listed in Table 1.
A touch-down PCR protocol was used, with cycling con-
ditions as follows: 95ºC for 15 minutes; 94ºC for 20 sec-
onds; 65ºC for 30 seconds; 72ºC for 30 seconds; steps 2
to 4 repeated for five cycles; 94ºC for 20 seconds; 58ºC
for 30 seconds; 72ºC for 30 seconds; steps 5 to 7
repeated for five cycles; 94ºC for 20 seconds; 53ºC for
30 seconds; 72ºC for 30 seconds; steps 8 to 10 repeated
for 38 cycles; and final extension at 72ºC for 3 minutes.
Each genotyping plate contained a mixture of case and
control samples.
General PCR conditions for amplifying products prior
to sequencing were as follows: 95ºC for 15 minutes, and
then 40 cycles of 95ºC for 30 seconds, 55 to 65ºC for 30
seconds, and 72ºC for 60 seconds, followed by 72ºC for
5 minutes. Direct sequencing was performed using Big-
Dye v3.1 terminator mix (Applied Biosystems, Foster
City, CA, USA) followed by ethanol precipitation. Plates
were run on an ABI 3700 capillary sequencer and
sequence analysis was performed with the Lasergene
DNAstar package using SeqMan software (DNASTAR
Inc., Madison, WI, USA). Primer sequences are listed in
Table 2.
Statistical analysis
Statistical analysis of genotype associations and logistic
regression was performed using the program SPSS v16.0
(SPSS, Inc., Chicago, IL, USA). Two-tailed tests of sig-
nificance were used for all analysis. Uncorrected P
values are presented throughout; appropriate signifi-
cance thresholds in the setting of multiple testing are
described in the Discussion. Tarone’s homogeneity of
odds ratio (OR) testing was performed to compare ORs
between study groups; if appropriate, study groups were
combined and stratified using Mantel-Haenszel testing
(SPSS v16.0). Analysis of LD was performed using the
Haploview v4.1 program [23]. Haplotype blocks were
defined as regions demonstrating strong evidence of his-
torical recombination between <5% of SNP-pair com-
parisons [24]. All control genotype distributions were in
Hardy-Weinberg equilibrium.
Results
The initial genotyping approach utilised the UK Cauca-
sian IPD case-control study group and focused on three
SNPs within NFKBIL2: rs760477, rs2306384, and
rs4082353. Whilst both rs760477 and rs4082353 are
intronic, rs2306384 encodes a serine/glycine substitution
at position 334 of the IB-R protein. Each of these
SNPs was found to be common in Europeans (minor
allele frequencies approaching 50%) and to associate
with susceptibility to IPD (P = 0.002 to 0.007; Table 3).
Logistic regression analysis demonstrated no effect of
age, comorbidity or gender on genotype. Genotyping
was then extended to flanking SNPs in both directions
spanning a 74 kb region across chromosome 8q24.3 to
delineate the extent of LD and disease association.
Twelve SNPs were found to be either nonpolymorphic
or extremely rare (minor allele frequency <0.01) and
could not be analysed further (Table 3). A further six
SNPs were polymorphic, of which two associated with
IPD susceptibility at the 0.05 significance level and
one trended towards association (P = 0.035 to 0.085;
Table 3). In each case the minor alleles were again found
to be common, and the direction of association was one
of heterozygote protection against IPD (Table 3).
The extent of LD between SNPs was next assessed. All
five IPD-associated SNPs were found to be located
within a 20 kb block of strong LD in this European
population (Figure 1). The absence of association with
SNPs outside this block suggests that the causative locus
is indeed localised to this 20 kb region, which contains
the entire NFKBIL2 gene as well as the neighbouring
gene in a 3’ direction, vacuolar protein sorting 28
(VPS28). This extensive LD presents a considerable
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challenge, however, in identifying the IPD-causative
polymorphism. The extent of LD in African populations
is typically shorter than in Europeans [24], and this can
be advantageous when attempting to fine map an exten-
sive region of disease association. With this in mind, all
nine polymorphisms were then genotyped in the Kenyan
bacteraemia case-control study (Tables 4 and 5).
The LD was noted to be much less extensive in this
African population, and no haplotype blocks were
predicted by the Gabriel algorithm within the region
studied (Figure 2).
Two of the NFKBIL2 SNPs genotyped were found to
be significantly associated with susceptibility to Gram-
positive and pneumococcal bacteraemia in Kenyan chil-
dren (rs4925858 and rs760477; Table 6). In each case
the direction of association was of heterozygote protec-
tion, the same genetic model as that observed in the UK
Caucasian study. Logistic regression analysis demon-
strated no effect of age, comorbidity, HIV infection or
gender on genotype. Comparison of ORs for rs4925858
and rs760477 did not demonstrate any evidence of het-
erogeneity between the UK and Kenyan case-control
groups for either SNP. The strongest association was
with rs760477; on combining and stratifying the UK and
Kenyan study groups, heterozygosity at rs760477 was
associated with significant protection against invasive
bacterial disease overall (IPD in the UK study and over-
all bacteraemia in the Kenyan study; Mantel-Haenszel
2 × 2 c2 = 18.567, P = 1.6 × 10-5, OR = 0.66, 95% confi-
dence interval for OR = 0.55 to 0.80) and against inva-
sive pneumococcal disease specifically (Mantel-Haenszel
2 × 2 c2 = 11.797, P = 0.0006, OR = 0.67, 95% confi-
dence interval for OR = 0.53 to 0.84). Heterozygosity at
the neighbouring SNP rs4925858 was also found to be
protective against both invasive bacterial disease overall
(Mantel-Haenszel 2 × 2 c2 = 8.610, P = 0.003, OR =
0.76, 95% confidence interval for OR = 0.63 to 0.91) and
IPD (Mantel-Haenszel 2 × 2 c2 = 9.104, P = 0.003, OR
= 0.70, 95% confidence interval for OR = 0.55 to 0.88).
None of the SNPs appeared to be associated with
Table 1 Primer sequences for NFKBIL2 polymorphism genotyping using the Sequenom Mass-Array® MALDI-TOF primer
extension assay
Polymorphism PCR primer sequences Extension primer sequences
rs10448143 ACGTTGGATGGGAACTGGAGCACGGGCTT CACGGGCTTCCCGTGGC
ACGTTGGATGAAGATGTCTCAGGGTCTTGG
rs2170096 ACGTTGGATGACTCCCAACCTCAGGTCATC GCTGGGATCACAGGCGTGAG
ACGTTGGATGAGAAATTGGGTTGTCAGCCG
rs4925858 ACGTTGGATGTGCAGGAGGCAGGAAATCCA GCAGGCCTGGGTGTGAG
ACGTTGGATGATGCTTTGGATGGGCAAGGG
rs760477 ACGTTGGATGAAAGGGAGGGCTCCAGAAGAC TCCAGAAGACGGGATTGCCCAA
ACGTTGGATGGCGTTTTCTGCCTCCTGAAC
rs2306384 ACGTTGGATGGGAAATGCAAGGTGCCGCTG TGCCGCTGGCCCTCACCGC
ACGTTGGATGAGCCACAGCGGAGAGCGAAG
rs4082353 ACGTTGGATGTAGTCTGCTCTGAAGGTTGG TGGAGAGACCAGAGGCAGA
ACGTTGGATGTGATCCCAGCTCCTAAAACC
rs2272658 ACGTTGGATGAACTGTTCCTGAGGCACTCC GAGGCACTCCAGGATGGAGC
ACGTTGGATGTAGAGCCCAGAGTGCTACCC
rs13258200 ACGTTGGATGAAAGTGACTGGCAGCTTCTG CCTCCTAGGGCTCTGAGTTCCTGC
ACGTTGGATGTGGTGGTGTTGGTGTAGTTG
rs4380978 ACGTTGGATGCAAAGCCTTCCAGTTTGGAC AGATGAAACGGGTGCCCC
ACGTTGGATGCTGCACACACTCACCATAAG
Table 2 Primer sequences used for direct sequencing
Name Forward primer sequence Reverse primer sequence
NFKBIL2_prom CGTCAGTCTATCTGGACAC CTCGCGCTCCAGGCTCATGCTC
NFKBIL2_ex1_2 GAGCATGAGCCTGGAGCGCGAG CAAGGCTGCGTCAGGTCAGGTG
NFKBIL2_int2 CACCTGACCTGACGCAGCCTTG CAGTGGCTTCACGCTGTATGCAGC
NFKBIL2_ex3 GCTGCATACAGCGTGAAGCCACTG GGATAAAGAGCTGACGATCTCCAG
NFKBIL2_ex4 CTGGAGATCGTCAGCTCTTTATCC TACTTCCTCCAGGAACAAG
NFKBIL2_ex5_6 CTTGTTCCTGGAGGAAGTA GAGAGCCCTGTACACACCTG
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outcome of bacteraemia in these groups (data not
shown), although the number of individuals in the poor
outcome groups was small (mortality rates were 10% in
the UK IPD study and 28% in the Kenyan study), result-
ing in a lack of power to examine possible effects of
genotype on mortality.
The SNP rs760477 is located within the fourth intron
of NFKBIL2. The first seven exons of NFKBIL2, which
surround rs760477, were then sequenced in 48 Kenyan
individuals in an attempt to identify novel and poten-
tially functional variants. The sequencing covered a
3,100 base pair region extending in a 3’ direction from
780 base pairs prior to the start of transcription in exon
1. No novel exonic polymorphisms were identified with
the exception of a synonymous polymorphism encoding
asparagine at position 23 of the IB-R protein, which
has subsequently been listed on databases and named
rs35913924. This SNP was then genotyped in the Ken-
yan cases and controls: the mutant allele was found to
be uncommon (allele frequency 3.6%), and no associa-
tion with disease was identified (3 × 2 c2 = 0.37, P =
0.83). The sequencing also confirmed the genotyping
accuracy of rs760477 (100% concordance between direct
sequencing and Sequenom genotyping).
Table 3 NFKBIL2 and flanking gene polymorphism genotype frequencies in European individuals with IPD and
controls
Polymorphism/locationa (major/minor
allele)
Status Genotype distributionb Genotypic 3 × 2
chi-square (P
value)
Heterozygote protection
modelc
AA Aa aa OR (95% CI) P valued
rs10448143, -5,224, 5’ upstream (C/T) Control 203 (57.7%) 126 (35.8%) 23 (6.5%) 1.245 (0.537) 1.17 (0.79 to 1.72) 0.425
IPD 88 (56.1%) 62 (39.5%) 7 (4.5%)
rs2170096, -4,368, 5’ upstream (C/G) Control 164 (24.3%) 349 (51.7%) 162 (24.0%) 4.927 (0.085) 0.71 (0.51 to 0.99) 0.036
IPD 53 (26.4%) 87 (43.3%) 61 (30.3%)
rs4925858, -3,771, 5’ upstream (G/A) Control 185 (27.1%) 360 (52.7%) 138 (20.2%) 6.664 (0.036) 0.69 (0.50 to 0.95) 0.016
IPD 66 (29.6%) 97 (43.5%) 60 (26.9%)
rs760477, -263, NFKBIL2 intron 4 (C/T) Control 188 (26.3%) 370 (51.7%) 158 (22.1%) 9.810 (0.007) 0.64 (0.48 to 0.85) 0.002
IPD 82 (31.3%) 106 (40.5%) 74 (28.2%)
rs2306384, +2,754, Ser/Gly, NFKBIL2 exon
11 (A/G)
Control 158 (24.6%) 336 (52.4%) 147 (22.9%) 12.329 (0.002) 0.61 (0.45 to 0.83) 0.001
IPD 67 (27.0%) 100 (40.3%) 81 (32.7%)
rs4082353, +12,589, NFKBIL2 intron 25 (G/T) Control 175 (27.2%) 327 (50.8%) 142 (22.0%) 9.932 (0.007) 0.66 (0.49 to 0.89) 0.005
IPD 70 (28.6%) 99 (40.4%) 76 (31.0%)
rs2272658, +16,899, VPS28 intron 4 (C/T) Control 156 (24.6%) 330 (52.1%) 147 (23.2%) 6.684 (0.035) 0.68 (0.49 to 0.95) 0.023
IPD 47 (25.7%) 78 (42.6%) 58 (31.7%)
rs13258200, +36,964, CPSF1 intron 2 (A/C) Control 258 (39.2%) 317 (48.1%) 84 (12.7%) 0.364 (0.833) 0.95 (0.72 to 1.26) 0.739
IPD 107 (38.9%) 129 (46.9%) 39 (14.2%)
rs4380978, +68,695, ADCK5 intron 1 (G/C) Control 212 (31.7%) 347 (51.9%) 110 (16.4%) 0.227 (0.893) 0.94 (0.70 to 1.26) 0.696
IPD 78 (32.0%) 123 (50.4%) 43 (17.6%)
VPS28, vacuolar protein sorting 28; CPSF1, cleavage and polyadenylation-specific factor 1; ADCK5, aarF domain-containing kinase 5; OR, odds ratio; CI, confidence
interval; IPD, invasive pneumococcal disease. The following NFKBIL2 SNPs were nonpolymorphic or very rare (minor allele frequency <0.01) in the UK Caucasian
population studied: rs7459910; rs2306383; rs4448319; rs3802163; rs4925856; rs2242264; rs2620660; rs741970; rs4925857; rs6985339; rs2928378; rs12677973. aSNP
positions listed are relative to the start of translation (in exon 5). bNumber of individuals (%). cComparison of heterozygotes [Aa] with homozygotes [AA + aa].
d2 × 2 chi-squared comparison, one degree of freedom. P values below 0.05 are highlighted in bold.
Figure 1 Relative position of SNPs and linkage disequilibrium
map for NFKBIL2 in the UK populations studied. Polymorphisms
are identified by their dbSNP rs numbers, and their relative positions
are marked by vertical lines within the white horizontal bar.
Numbers within squares indicate the D’ value expressed as a
percentile. Red squares indicate pairs in strong linkage
disequilibrium (LD) with LOD scores for LD ≥2, pink squares D’ <1
with LOD ≥2, and white squares D’ <1.0 and LOD <2.
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Discussion
In this study we demonstrate associations between com-
mon NFKBIL2 polymorphisms and susceptibility to IPD
in UK Caucasian and Kenyan individuals. Important
causes of false positive associations in genetic studies
are a failure to adjust significance levels when multiple
polymorphisms have been analysed, and confounding by
population substructure. Nine polymorphisms were ana-
lysed, and applying a Bonferroni correction results in a
threshold significance level of 0.0055, rather than 0.05.
With this corrected significance level, rs760477,
rs2306384 and rs4082353 in the UK population remain
associated with protection against IPD. The Bonferroni
correction, however, assumes that markers are indepen-
dent, whereas many of the polymorphisms studied here
are in strong or complete LD in UK individuals and are
therefore not truly independent from each other. Apply-
ing instead a correction based on the total number of
LD blocks and singleton (not part of a LD block) poly-
morphisms, five independent tests were performed in
the UK study group, suggesting a threshold P value of
0.01 for statistical significance. The extent of LD was
much less in Kenyan individuals, and as a result no LD
blocks were predicted (Figure 2). In this setting, none of
the polymorphisms in the Kenyan study reaches the
Bonferroni-corrected P value threshold of 0.0055 to
declare significance. Nevertheless, given the observed
association between NFKBIL2 SNPs and IPD in UK
individuals, the a priori probability that such a SNP pro-
tects against IPD in the Kenyan population might be
expected to be higher than for a random marker, and in
this situation the Bonferroni adjustment may be overly
stringent. It is also noteworthy that the SNPs rs4925858
and rs760477 trend or associate in the same direction
(heterozygote protection) in the Kenyan study as that
observed in the UK study group, and combined analysis
of the UK and Kenyan study groups using the Mantel-
Haenszel test further strengthens the association
between NFKBIL2rs760477 and IPD.
Addressing the possibility of population substructure,
recent analysis of an extensive dataset of over 15,000
individuals from Britain demonstrated remarkably little
evidence of geographic population differentiation within
British Caucasians [18], and moreover our cases and
controls are from a relatively restricted geographic area
(Oxfordshire). Furthermore, the observation of a trend
towards heterozygote protection against IPD in a sec-
ond, independent study of African individuals provides
additional support for an association between NFKBIL2
polymorphisms and pneumococcal disease. The results
of the Kenyan study additionally suggest that the
NFKBIL2 association may be with bacteraemia overall,
rather than a specific effect on pneumococcal suscept-
ibility, although this finding requires replication.
In general, a possible disadvantage for the use of the
Kenyan samples as a replication study group is their dif-
ferent ethnic background: a lack of replication may
reflect true ethnic heterogeneity in pneumococcal dis-
ease susceptibility. On the other hand, the study of a
second population with differing patterns of LD may aid
fine-mapping of associations within regions of strong
LD, and it has been suggested that the demonstration of
genetic associations with disease susceptibility across
different populations is perhaps of even more value than
the identification of population-specific effects [25]. The
IPD-associated polymorphisms in the UK Caucasian
study span a distance of 20 kb including the genes
NFKBIL2 and VPS28. On the basis of these results alone
it is not possible to further localise the disease associa-
tion within this region, although the associations within
the Kenyan study group appear to focus the association
within NFKBIL2. Despite the use of such a transethnic
mapping approach, the functional variant in NFKBIL2
that is responsible for the association with IPD remains
unknown. Perhaps the most probable functional variant
Table 4 NFKBIL2 and flanking gene polymorphism allele
frequencies: European IPD and African bacteraemia
case-control studies
Polymorphism/
location
UK Caucasian study Kenyan study
Minor allele
frequency
(%)
P valuea Minor allele
frequency
(%)
P valuea
rs10448143,
-5,224
24.3 0.537 4.7 0.250b
rs2170096, -4,368 49.6 0.085 38.2 0.145
rs4925858, -3,771 47.1 0.036 30.7 0.128
rs760477, -263 48.1 0.007 25.7 0.009
rs2306384, +2,754 49.8 0.002 33.5 0.427
rs4082353,
+12,589
48.5 0.007 33.4 0.857
rs2272658,
+16,899
49.9 0.035 36.7 0.927
rs13258200,
+36,964
37.0 0.833 40.2 0.801
rs4380978,
+68,695
42.5 0.893 32.6 0.648
aP values are derived from 3 × 2 chi-squared comparisons of genotypes (two
degrees of freedom). bFisher’s exact test (two-tailed). P values below 0.05 are
highlighted in bold.
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within NFKBIL2 is the coding change rs2306384, but it
is noteworthy that this association did not replicate in
the Kenyan study group. The SNP rs760477 is located
within intron 4 and is unlikely itself to exert a functional
effect, and no disease-associated polymorphisms were
identified in the surrounding exons. The polymorphism
rs4925858 is located 1,650 base pairs before the tran-
scription start, and could conceivably affect a regulatory
region such as a promoter, enhancer or silencer.
The mechanism by which IB-R variation influences
susceptibility to IPD is also unclear. One possibility is
through an effect on CCL5 expression, which has been
reported to be upregulated in lung epithelial cells fol-
lowing overexpression of IB-R [16]. The mechanism
behind this cytokine-induced upregulation appears to be
sequestering of transcriptionally repressive NF-B p50
homodimer subunits by IB-R, thereby facilitating NF-
B-mediated gene transcription of CCL5 [16]. Both
CCL5 mRNA and protein expression are stimulated fol-
lowing exposure to the pneumococcal proteins pneumo-
lysin and choline-binding protein A in dendritic cells,
and furthermore CCL5 blockade during pneumococcal
carriage in mice is associated with an attenuated
immune response and greater transition to lethal pneu-
monia [26,27]. Further research is required to examine
the possible role of IB-R in regulation of CCL5 during
pneumococcal disease, and indeed to identify the cellu-
lar roles of IB-R more generally. This protein has been
relatively neglected compared with the extensive litera-
ture on other IBs, and it remains unclear for example
which specific NF-B dimers interact with IB-R
[14,16].
The direction of association with disease is note-
worthy: heterozygosity was associated with protection
against IPD in each study population. The finding of
heterozygote protection is unusual in genetic disease
association studies, but is well described in the study of
human infectious disease genetic susceptibility - exam-
ples include sickle cell trait and malaria, prion protein
gene variation and spongiform encephalopathy, and
human leukocyte antigen and HIV/AIDS disease pro-
gression [28-30]. More recently, heterozygosity at loci
within both the Toll-like receptor adaptor protein Mal/
TIRAP and NFKBIZ have been found to associate with
Table 5 NFKBIL2 and flanking gene polymorphism genotype frequencies in Kenyan individuals with bacteraemia and
controls
Polymorphism/locationa (major/
minor allele)
Status Genotype distributionb Genotypic 3 × 2
chi-square
(P value)
Heterozygote protection
modelc
AA Aa aa OR (95% CI) P valued
rs10448143, -5,224, 5’ upstream (C/T) Control 433 (89.6%) 50 (10.4%) 0 (0%) 0.250e 0.78 (0.52 to 1.17) 0.226
Bacteraemia 598 (91.4%) 54 (8.3%) 2 (0.3%)
rs2170096, -4,368, 5’ upstream (C/G) Control 128 (38.7%) 136 (41.1%) 67 (20.2%) 0.145 0.93 (0.66 to 1.31) 0.672
Bacteraemia 107 (45.7%) 92 (39.3%) 35 (15.0%)
rs4925858, -3,771, 5’ upstream (G/A) Control 255 (46.4%) 247 (44.9%) 48 (8.7%) 0.128 0.80 (0.64 to 1.00) 0.053
Bacteraemia 343 (49.9%) 271 (39.4%) 73 (10.6%)
rs760477, -263, NFKBIL2 intron 4 (C/T) Control 262 (53.0%) 192 (38.9%) 40 (8.1%) 0.009 0.68 (0.53 to 0.87) 0.002
Bacteraemia 403 (60.6%) 201 (30.2%) 61 (9.2%)
rs2306384, +2,754, Ser/Gly, NFKBIL2
exon 11 (A/G)
Control 238 (45.0%) 224 (42.3%) 67 (12.7%) 0.427 0.84 (0.65 to 1.09) 0.195
Bacteraemia 214 (47.9%) 171 (38.3%) 62 (13.8%)
rs4082353, +12,589, NFKBIL2 intron
25 (G/T)
Control 160 (47.6%) 132 (39.3%) 44 (13.1%) 0.857 1.05 (0.75 to 1.47) 0.785
Bacteraemia 109 (45.4%) 97 (40.4%) 34 (14.2%)
rs2272658, +16,899, VPS28 intron 4 (C/T) Control 135 (40.9%) 145 (43.9%) 50 (15.2%) 0.927 0.96 (0.69 to 1.33) 0.791
Bacteraemia 113 (42.5%) 114 (42.9%) 39 (14.7%)
rs13258200, +36,964, CPSF1 intron
2 (A/C)
Control 212 (37.7%) 245 (43.6%) 105 (18.7%) 0.801 1.06 (0.85 to 1.33) 0.601
Bacteraemia 259 (37.5%) 311 (45.1%) 120 (17.4%)
rs4380978, +68,695, ADCK5 intron 1 (G/C) Control 246 (45.6%) 231 (42.8%) 63 (11.6%) 0.648 0.90 (0.71 to 1.13) 0.352
Bacteraemia 329 (47.7%) 277 (40.1%) 84 (12.2%)
VPS28, vacuolar protein sorting 28; CPSF1, cleavage and polyadenylation-specific factor 1; ADCK5, aarF domain-containing kinase 5; OR, odds ratio; CI, confidence
interval; IPD, invasive pneumococcal disease. aSNP positions listed are relative to the start of translation (in exon 5). bNumber of individuals (%). cComparison of
heterozygotes [Aa] with homozygotes [AA + aa]. d2 × 2 chi-squared comparison, one degree of freedom. eFisher’s exact test (two-tailed). P values below 0.05 are
highlighted in bold.
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protection against IPD [10,31]. Interestingly, studies in
animal populations have found that increased levels of
genome-wide heterozygosity correlate with overall fit-
ness, and more specifically with resistance to infectious
disease; for example, resistance to bovine tuberculosis in
the Iberian wild boar [32]. These animal studies raise
the possibility that heterozygote advantage against infec-
tious disease may be a more widespread phenomenon in
humans than previously considered. The biological
mechanisms that underlie this remain unclear, although
in the setting of inflammatory signalling pathways it has
been speculated that homozygote states may lead to
extremes of inflammatory response that, under certain
circumstances, are detrimental to the host, whereas het-
erozygosity may result in intermediate signalling that
leads to an optimal inflammatory response [31]. Such a
model will be further modified by environmental expo-
sures, and differing burdens of bacterial disease may in
part account for the observed variation in NFKBIL2
allele frequencies between European and African
populations.
Finally, it is interesting that four out of the five IB
genes studied to date show apparent associations with
susceptibility to IPD [9,10]. This further highlights the
importance of the control of NF-B in the host immune
response, and suggests that the remaining members of
the IB family are likely to be promising candidates for
a role in pneumococcal susceptibility. Study of the
genetic basis of NF-B inhibition may be increasingly
relevant given current interest in the regulation of
NF-B activity as a therapeutic target for inflammatory
disease [33]. Within the field of infectious disease, inhi-
bition of NF-B has been demonstrated to improve out-
come in animal models of sepsis and pneumococcal
meningitis [34,35]. The anti-inflammatory activity of
glucocorticoids is mediated at least in part through phy-
sical interference of the glucocorticoid receptor complex
with NF-B DNA binding and increased synthesis of
Figure 2 Relative position of SNPs and linkage disequilibrium
map for NFKBIL2 in the Kenyan populations studied.
Polymorphisms are identified by their dbSNP rs numbers, and their
relative positions are marked by vertical lines within the white
horizontal bar. Numbers within squares indicate the D’ value
expressed as a percentile. Red squares indicate pairs in strong
linkage disequilibrium (LD) with LOD scores for LD ≥2, pink squares
D’ <1 with LOD ≥2, and white squares D’ <1.0 and LOD <2.
Table 6 NFKBIL2 polymorphism genotype frequencies in Kenyan children with bacteraemia (overall, Gram-positive,
and pneumococcal) and controls
Polymorphism/location (major/
minor allele)
Status Genotype distributiona Total Genotypic 3 × 2 chi-square
(P value)
Heterozygote
protection modelb
AA Aa aa OR (95% CI) P valuec
rs4925858, -3,771, 5’ upstream
(G/A)
Control 255
(46.4%)
247
(44.9%)
48
(8.7%)
550 4.104 (0.128) 0.80 (0.64 to
1.00)
0.053
Bacteraemia 343
(49.9%)
271
(39.4%)
73
(10.6%)
687
Gram-positive
bacteraemia
167
(49.9%)
125
(37.3%)
43
(12.8%)
335 6.806 (0.034) 0.73 (0.55 to
0.96)
0.026
Pneumococcal
bacteraemia
83
(48.8%)
62
(36.5%)
25
(14.7%)
170 6.900 (0.032) 0.70 (0.49 to
1.00)
0.052
rs760477, -263, intron 4 (C/T) Control 262
(53.0%)
192
(38.9%)
40
(8.1%)
494 9.445 (0.009) 0.68 (0.53 to
0.87)
0.002
Bacteraemia 403
(60.6%)
201
(30.2%)
61
(9.2%)
665
Gram-positive
bacteraemia
197
(60.4%)
97
(29.8%)
32
(9.8%)
326 7.205 (0.027) 0.67 (0.49 to
0.90)
0.007
Pneumococcal
bacteraemia
93
(56.4%)
52
(31.5%)
20
(12.1%)
165 4.259 (0.119) 0.72 (0.50 to
1.05)
0.090
OR, odds ratio; CI, confidence interval. aNumber of individuals (%). bComparison of heterozygotes [Aa] with homozygotes [AA + aa]. c2 × 2 chi-squared
comparison, one degree of freedom. P values below 0.05 are highlighted in bold.
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IB [36], and there is some evidence of benefit from
corticosteroids in the treatment of pneumococcal
meningitis and perhaps also severe community-acquired
pneumonia [37,38]. Taken together, these findings raise
the intriguing possibility that anti-inflammatory treat-
ments such as glucocorticoids may be more effective if
tailored on the basis of an individual’s genetic profile of
NF-B activation.
Conclusions
Our study demonstrates associations between common
NFKBIL2 polymorphisms and susceptibility to IPD in
European and African populations. These findings
further support a central role for regulation of NF-B in
human host defence against pneumococcal disease.
Key messages
• Common polymorphisms in the gene NFKBIL2 associ-
ate with susceptibility to IPD in European and African
populations.
• The parallel study of disease phenotypes in European
and African populations (a trans-ethnic mapping
approach) facilitates fine-mapping of genetic associations
within regions of strong LD.
• Genetic variation in control of the proinflammatory
transcription factor NF-B appears to play a key role in
host defence against pneumococcal disease.
Abbreviations
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